Segment Data (Tables)

3 Months Ended

Mar. 31, 2023

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:



	Successor		Predecessor
	Three Months Ended March 31, 2023		Three Months Ended April 1, 2022
Net sales:
Specialty Brands	$	252.0	$	339.4
Specialty Generics	172.6		151.5
Net sales	$	424.6	$	490.9
Operating income (loss):
Specialty Brands	$	32.4	$	164.8
Specialty Generics	32.8		34.4
Segment operating income	65.2		199.2
Unallocated amounts:
Corporate and unallocated expenses (1)	(14.0)		(32.8)
Depreciation and amortization	(145.1)		(177.2)
Share-based compensation	(2.6)		(1.2)
Restructuring charges, net	(1.2)		(6.8)

Separation costs (2)	(4.9)		(2.0)


Operating loss	$	(102.6)	$	(20.8)

(1)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(2)Represents costs included in selling, general and administrative expenses, primarily related to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:



	Successor		Predecessor
	Three Months Ended March 31, 2023		Three Months Ended April 1, 2022
Acthar Gel	$	82.0	$	127.7
INOmax	82.7		99.0
Therakos	58.7		59.9
Amitiza (1)	24.5		47.7
Terlivaz	2.2		—
Other	1.9		5.1
Specialty Brands	252.0		339.4

Opioids	62.2		50.0
ADHD	22.4		10.8
Addiction treatment	15.6		15.9
Other	1.8		2.8
Generics	102.0		79.5
Controlled substances	18.5		20.4
APAP	46.4		46.3
Other	5.7		5.3
API	70.6		72.0
Specialty Generics	172.6		151.5
Net sales	$	424.6	$	490.9

(1)Amitiza consists of both product net sales and royalties. Refer to Note 2 for further details on Amitiza's revenues.